The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®)

Charlotte Höybye, Lars Sävendahl, Henrik Thybo Christesen, Peter Lee, Birgitte Tønnes Pedersen, Michael Schlumpf, John Germak, Judith Ross, Charlotte Höybye, Lars Sävendahl, Henrik Thybo Christesen, Peter Lee, Birgitte Tønnes Pedersen, Michael Schlumpf, John Germak, Judith Ross

Abstract

Objective: Randomized controlled trials have shown that growth hormone (GH) therapy has effects on growth, metabolism, and body composition. GH therapy is prescribed for children with growth failure and adults with GH deficiency. Carefully conducted observational study of GH treatment affords the opportunity to assess long-term treatment outcomes and the clinical factors and variables affecting those outcomes, in patients receiving GH therapy in routine clinical practice.

Design: The NordiNet® International Outcome Study (IOS) and the American Norditropin®

Studies: Web Enabled Research (ANSWER Program®) are two complementary, non-interventional, observational studies that adhere to current guidelines for pharmacoepidemiological data.

Patients: The studies include pediatric and adult patients receiving Norditropin®, as prescribed by their physicians.

Measurements: The studies gather long-term data on the safety and effectiveness of reallife treatment with the recombinant human GH, Norditropin®. We describe the origins, aims, objectives, and design methodology of the studies, as well as their governance and validity, strengths, and limitations.

Conclusion: The NordiNet® IOS and ANSWER Program® studies will provide valid insights into the effectiveness and safety of GH treatment across a diverse and large patient population treated in accordance with real-world clinical practice and following the Good Pharmacoepidemiological Practice and STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidelines.

Keywords: growth hormone replacement therapy; pharmacoepidemiology; survey; treatment outcome.

References

    1. Hartung DM, Touchette D. Overview of clinical research design. Am J Health Syst Pharm. 2009;66(4):398–408.
    1. Mann CJ. Observational research methods. Research design II: cohort, cross sectional, and case-control studies. Emerg Med J. 2003;20(1):54–60.
    1. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–349.
    1. McNeil JJ, Piccenna L, Ronaldson K, Ionnides-Demos LL. The value of patient-centred registries in phase IV drug surveillance. Pharma Med. 2010;24(5):281–288.
    1. Glasziou P, Vandenbroucke JP, Chalmers I. Assessing the quality of research. BMJ. 2004;328(7430):39–41.
    1. Growth Hormone Research Society Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab. 2000;85(11):3990–3993.
    1. Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab. 2001;86(5):1868–1870.
    1. Clayton PE, Cuneo RC, Juul A, Monson JP, Shalet SM, Tauber M, European Society of Paediatric Endocrinology Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol. 2005;152(2):165–170.
    1. Ho KK. GH Deficiency Consensus Workshop Participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol. 2007;2007;157(6):695–700.
    1. Gutiérrez LP, Koltowska-Häggström M, Jönsson PJ, et al. Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database) Pharmacoepidemiol Drug Saf. 2008;17(1):90–102.
    1. Gharib H, Cook DM, Saenger PH, et al. American Association of Clinical Endocrinologists Growth Hormone Task Force American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children—2003 update. Endocr Pract. 2003;9(1):64–76.
    1. Molitch ME. Growth hormone treatment in adults with growth hormone deficiency: the transition. J Endocrinol Invest. 2011;34(2):150–154.
    1. Norditropin® [homepage on the Internet] Princeton, NJ: Novo Nordisk Inc; 2012Available from: Accessed December 27, 2012
    1. Novo Nordisk Inc Summary of Product Characteristics [Norditropin® SimpleXx®] Bagsværd: Novo Nordisk Inc; 2012Available from: Accessed December 27, 2012
    1. Novo Nordisk Inc Summary of Product Characteristics [Norditropin® NordiFlex®] Bagsværd: Novo Nordisk Inc; 2012Available from: Accessed December 27, 2012
    1. Novo Nordisk Inc Summary of Product Characteristics [Norditropin® FlexPro®] Bagsværd: Novo Nordisk Inc; 2012Available from: Accessed December 27, 2012
    1. Novo Nordisk Observational prospective study on patients treated with Norditropin® ClinicalTrialsgov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2009[updated January 4, 2013]Available from: NLM identifier: NCT00960128Accessed February 20, 2013
    1. Novo Nordisk An observational study (Registry) assessing treatment outcomes and safety for children and adults who are prescribed Norditropin® (Human Growth Hormone) (ANSWER) ClinicalTrialsgov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2009[updated January 11, 2013]Available from: NLM identifier: NCT01009905Accessed February 20, 2013
    1. Novo Nordisk Safety and efficacy of long-term somatropin treatment in children (GrowthWIN II) ClinicalTrialsgov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2012[updated June 26, 2012]Available from: NLM identifier: NCT01543867Accessed December 27, 2012
    1. Novo Nordisk Safety and efficacy of long-term somatropin treatment in adults (NordiWIN) ClinicalTrialsgov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2012[updated June 26, 2012]Available from: NLM identifier: NCT01543880Accessed December 27, 2012
    1. Guidelines for Good Pharmacoepidemiology Practices (GPP) Revised April 2007Available from: Accessed March 12, 2013
    1. International Classification of Diseases 10th Revision (ICD-10) Available from Accessed March 12, 2013
    1. Thodberg HH, van Rijn RR, Tanaka T, Martin DD, Kreiborg S. A paediatric bone index derived by automated radiogrammetry. Osteoporos Int. 2010;21(8):1391–1400.
    1. Lee PA, Germak J, Gut R, Khutoryansky N, Ross J. Identification of factors associated with good response to growth hormone therapy in children with short stature: results from the ANSWER Program®. Int J Pediatr Endocrinol. 2011;2011:6.
    1. Lee PA, Sävendahl L, Oliver I, et al. Comparison of response to 2-years’ growth hormone treatment in children with isolated growth hormone deficiency, born small for gestational age, idiopathic short stature, or multiple pituitary hormone deficiency: combined results from two large observational studies. Int J Pediatr Endocrinol. 2012;2012(1):22.
    1. Lee PA, Ross J, Germak JA, Gut R. Effect of 4 years of growth hormone therapy in children with Noonan syndrome in the American Norditropin Studies: Web-Enabled Research (ANSWER) Program® registry. Int J Pediatr Endocrinol. 2012;2012(1):15.
    1. Ross J, Lee PA, Gut R, Germak J. Impact of age and duration of growth hormone therapy in children with Turner syndrome. Horm Res Paediatr. 2011;76(6):392–399.
    1. Sävendahl L, Blankenstein O, Oliver I, et al. Gender infuences short-term growth hormone treatment response in children. Horm Res Paediatr. 2012;77(3):188–194.
    1. Ross J, Lee PA, Gut R, Germak J. Factors influencing the one- and two-year growth response in children treated with growth hormone: analysis from an observational study. Int J Pediatr Endocrinol. 2010;2010:494656.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner